Krishna Institute of Medical Sciences Limited (KIMS) AI Stock Analysis

• Market Cap: ₹287.70B
• Dividend Yield: N/A
• Average Volume (3M): 23.04K
• Price to Earnings (P/E): 95.7
• Beta (1Y): 0.55
• Revenue Growth: 25.74%
• EPS Growth: 1.41%
• Country: IN
• Employees: 5,013
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 1.30
• Shares Outstanding: 400,138,950
• 10 Day Avg. Volume: 26,167
• 30 Day Avg. Volume: 23,042
• PEG Ratio: 2.68
• Price to Book (P/B): 11.57
• Price to Sales (P/S): 8.15
• P/FCF Ratio: -57.91
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹814.00
• Price Target Upside: 24.66% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): 7.88
• Revenue Forecast (FY): ₹38.77B

• Rating: 65 Neutral
• Price Target: ₹640.00 ▼(-1.99% Downside)
• Action: Reiterated Date: 10/14/25
• Date: Action: Reiterated 10/14/25

Krishna Institute of Medical Sciences Limited demonstrates strong financial performance with significant revenue and profit growth. However, the stock's high valuation and bearish technical indicators suggest caution. The company's increased leverage and negative free cash flow are potential risks that need monitoring.

Positive Factors

Revenue Growth Trajectory

Sustained revenue growth nearly doubling over three years indicates durable demand for tertiary and quaternary care across the company’s hospital network. Growing volumes and service mix support scale economics, capacity utilization and long-term revenue resilience beyond short-term cycles.

Stable Margins and Improving Profitability

Consistently high gross margins and improving net margin, combined with an 18% ROE, reflect structural operating strength and effective cost control in clinical operations. These durable margin levels support cash generation and reinvestment capacity as the hospital network scales.

Robust Operating Cash Generation

Strong operating cash flow and an OCF-to-net-income ratio above 1 indicate high earnings quality and persistent cash conversion from hospital operations. This foundation underpins long-term funding for working capital and expansion, lessening reliance on volatile external financing.

Negative Factors

Rising Leverage

Higher leverage increases fixed interest obligations and financial risk for a capital-intensive hospital operator. With debt-to-equity at 1.20, the company is more exposed to interest-rate cycles and may face constrained flexibility for future investments or slower deleveraging during downturns.

Negative Free Cash Flow

Persistent negative free cash flow driven by heavy capex for expansions and equipment can strain liquidity and force reliance on external funding. Over the medium term this can pressure balance sheet flexibility and raise cost of capital if investment pacing isn’t matched by sustained cash generation.

Weak EPS Trend

Negative EPS growth despite revenue expansion suggests profit volatility from non-operating costs, higher interest, or upfront investment expenses. Continued EPS declines can undermine investor confidence and indicate that earnings leverage from revenue growth is not yet fully realized.

Krishna Institute of Medical Sciences Limited Business Overview & Revenue Model

Company Description

Krishna Institute of Medical Sciences Limited provides medical and health care services under the KIMS Hospitals brand name in India. The company offers range of specialties, including cardiac, dental, neuro, oncological, orthopedic, renal, reproductive, and robotic sciences, as well as gastroenterology and hepatology, heart and lung transplant, organ transplantation, mother and childcare, and pediatrics services. It also focuses on accident, biochemistry, anesthesiology, bariatric surgery, andrology and infertility, arthroscopy, alzheimers, bone, joint center specialties, and others. The company was incorporated in 1973 and is based in Secunderabad, India.

How the Company Makes Money

KIMS generates revenue primarily through patient care services, including inpatient and outpatient treatments, surgeries, and diagnostic services. The company earns money by charging patients for hospital stays, medical procedures, consultations, and specialized treatments. Additional revenue streams include partnerships with insurance companies for cashless treatment options, government health schemes, and corporate tie-ups for employee health programs. KIMS may also benefit from ancillary services such as pharmacy sales, laboratory services, and health check-up packages, which contribute to its overall earnings.

Krishna Institute of Medical Sciences Limited Financial Statement Overview

Summary

Krishna Institute of Medical Sciences Limited shows strong financial health with significant revenue and profit growth, supported by stable margins. The company has a solid equity base, although increased leverage could pose some risk. Operational cash generation is robust, but high capital expenditures have led to negative free cash flow.

Income Statement

Krishna Institute of Medical Sciences Limited has demonstrated a robust revenue growth trajectory, increasing from 16.5 billion in 2022 to 30.4 billion in 2025, indicating strong market demand and operational efficiency. The gross profit margin remained stable around 62-63%, showcasing effective cost management. Notably, the net profit margin improved to 12.7% in 2025 from 12.4% in 2024, suggesting enhanced profitability. The EBIT margin also showed a strong increase to 62.9% in 2025, reflecting operational excellence. Overall, the company exhibits impressive growth and profitability.

Balance Sheet

The balance sheet of Krishna Institute of Medical Sciences Limited reflects a solid equity base with stockholders' equity increasing to 21.4 billion in 2025. The debt-to-equity ratio rose to 1.20 in 2025, indicating increased leverage which could pose a risk if not managed carefully. However, the equity ratio remains healthy at 37.3%, suggesting a stable financial foundation. Return on equity improved to 18% in 2025, signifying effective utilization of shareholder funds. While leverage has increased, the company maintains a strong equity position.

Cash Flow

The cash flow analysis reveals that operating cash flow has been steadily increasing, reaching 5.8 billion in 2025, highlighting robust operational performance. However, free cash flow has been negative, mainly due to high capital expenditures which could limit liquidity in the short term. The operating cash flow to net income ratio of 1.51 in 2025 suggests strong earnings quality. Despite the negative free cash flow, the company shows solid cash generation from operations.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	32.18B	30.35B	24.98B	21.98B	16.51B	13.30B
Gross Profit	22.12B	9.10B	14.82B	6.99B	10.34B	4.19B
EBITDA	8.24B	7.83B	6.53B	6.43B	5.46B	3.78B
Net Income	3.77B	3.85B	3.10B	3.36B	3.33B	2.01B
Balance Sheet
Total Assets	0.00	57.36B	38.52B	29.41B	19.07B	14.36B
Cash, Cash Equivalents and Short-Term Investments	1.02B	1.02B	1.32B	1.34B	1.90B	2.84B
Total Debt	0.00	25.57B	13.55B	6.78B	2.57B	3.16B
Total Liabilities	-24.19B	33.17B	17.59B	10.03B	4.97B	5.60B
Stockholders Equity	24.19B	21.38B	18.28B	16.70B	13.87B	8.64B
Cash Flow
Free Cash Flow	0.00	-4.27B	-1.26B	-1.42B	1.54B	2.62B
Operating Cash Flow	0.00	5.82B	5.21B	4.32B	3.24B	3.56B
Investing Cash Flow	0.00	-11.16B	-7.53B	-5.47B	-4.12B	-3.54B
Financing Cash Flow	0.00	5.43B	2.17B	196.42M	609.99M	98.19M

Krishna Institute of Medical Sciences Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 653.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:KIMS, the sentiment is Positive. The current price of 653 is below the 20-day moving average (MA) of 683.26, above the 50-day MA of 644.13, and below the 200-day MA of 689.73, indicating a bullish trend. The MACD of 28.12 indicates Negative momentum. The RSI at 60.49 is Neutral, neither overbought nor oversold. The STOCH value of 77.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:KIMS.

Krishna Institute of Medical Sciences Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NH	71 Outperform	₹365.11B	47.88	―	0.24%	14.72%	8.37%
HCG	67 Neutral	₹83.61B	411.79	―	―	17.58%	-38.20%
KIMS	65 Neutral	₹287.70B	95.68	―	―	25.74%	1.41%
MEDANTA	65 Neutral	₹303.07B	59.64	―	0.04%	15.78%	15.01%
ASTERDM	62 Neutral	₹335.22B	101.91	―	0.84%	-36.14%	-93.99%
FORTIS	61 Neutral	₹704.26B	74.10	―	0.11%	15.33%	54.62%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Krishna Institute of Medical Sciences Limited Corporate Events

KIMS Sets Post-Q3 FY26 Earnings Call to Outline Strategy and Outlook

Krishna Institute of Medical Sciences Limited has announced that its top management, including Founder and Managing Director Dr. Bhaskara Rao Bollineni, Executive Director and CEO Dr. Abhinay Bollineni, and Chief Financial Officer Mr. Sachin Salvi, will participate in an earnings conference call hosted by IIFL Capital on 7 February 2026. The call, which follows the release of the company’s third-quarter FY26 financial results, is intended for analysts and investors and will focus on discussing KIMS’s business strategy and outlook, underscoring the company’s efforts to maintain transparent communication with the market and provide stakeholders with deeper insight into its operational and strategic priorities.

KIMS Publishes Postal Ballot Notice and Confirms Completion of E-Voting Dispatch

Krishna Institute of Medical Sciences Limited has notified the stock exchanges that it has published a postal ballot notice in the Financial Express and Nava Telangana on 3 January 2026, detailing e-voting information for shareholders and confirming completion of dispatch of the notice. The move underscores KIMS’s adherence to statutory requirements under the Companies Act and SEBI’s Listing Regulations, reinforcing transparency and formal shareholder participation in corporate decision-making processes, with the related documents also made accessible via the company’s investor website.

KIMS Seeks Shareholder Nod for Material Related-Party Deal via Postal Ballot

Krishna Institute of Medical Sciences Limited has initiated a postal ballot process to seek shareholder approval for a material related-party transaction with its subsidiary, KIMS Hospital Bengaluru Private Limited. The company has set out the timetable for this electronic voting exercise, including a 30 December 2025 cut-off date for determining eligible members, dispatch of the ballot notice on 2 January 2026, and an e-voting window running from 3 January to 1 February 2026, indicating a formal step to regularize and gain shareholder consent for intra-group dealings that could influence its consolidated operations and governance framework.

KIMS to Enter Tamil Nadu with Rs 300 Crore Super-Speciality Hospital in Chennai

Krishna Institute of Medical Sciences Limited has entered into a long-term leave and license agreement with Andhra Mahila Sabha to lease approximately 1.168 acres of land in Raja Annamalai Puram, Chennai, for the establishment of a new super-speciality hospital. The planned facility will add around 300 beds to KIMS’s network within the next 36 months, requiring an estimated investment of Rs 300 crore funded through a mix of bank loans and internal accruals. This expansion marks KIMS’s first entry into Tamil Nadu, a strategic move aimed at enhancing its geographic presence, improving operational performance, and supporting sustainable long-term financial returns, even as the company currently operates at about 51% occupancy across its existing capacity.

Krishna Institute of Medical Sciences Releases Earnings Call Transcript

Krishna Institute of Medical Sciences Limited held an earnings conference call with investors and analysts on November 10, 2025. The transcript of this call has been made available on the company’s website. This initiative reflects the company’s commitment to transparency and effective communication with its stakeholders, potentially impacting its market perception positively.